Treatment of adult T-cell leukemia/lymphoma: Past, present, and future

European Journal of Haematology

Volumn 80, Issue 3, 2008, Pages 185-196

  Ishitsuka, Kenji ^a   Tamura, Kazuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Adult T cell leukemia lymphoma; Human T cell lymphotrophic virus type I; Novel therapy; Treatment

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; BETA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CALCITONIN; CARBOPLATIN; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; IRINOTECAN; METHOTREXATE; MITOXANTRONE; PENTOSTATIN; PEPLEOMYCIN; PIRARUBICIN; PREDNISOLONE; PROCARBAZINE; RANIMUSTINE; RETINOID DERIVATIVE; SOBUZOXANE; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; HEMATOLOGIC DISEASE; HUMAN; HYPERCALCEMIA; LYMPHOMA; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; STEM CELL TRANSPLANTATION; T CELL LEUKEMIA;

CLINICAL TRIALS AS TOPIC; FORECASTING; FRANCE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; JAPAN; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 39149111265     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01016.x     Document Type: Review

References (157)

1. Takatsuki K, Uchiyama T, Sagawa K, Yodoi J. [Surface markers of malignant lymphoid cells in the classification of lymphoproliferative disorders, with special reference to adult T-cell leukemia (author's transl)]. Rinsho Ketsueki 1976 17: 416 21.
2. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977 50: 481 92.
3. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980 77: 7415 9.
4. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981 78: 6476 80.
5. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985 2: 407 10.
6. Jeffery KJ, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999 96: 3848 53.
7. Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990 348: 245 8.
8. Yashiki S, Fujiyoshi T, Arima N, et al. HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 2001 17: 1047 61.
9. Bangham CR, Osame M. Cellular immune response to HTLV-1. Oncogene 2005 24: 6035 46.
10. Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology 2003 308: 1 12.
11. Gessain A. Epidemiology of HTLV-I and associated diseases. In: Hollsberg P, Hafler DA, eds. Human T-cell Lymphotropic Virus Type 1. New York: Wiley, 1996: 33 64.
12. Hanada S, Uematsu T, Iwahashi M, et al. The prevalence of human T-cell leukemia virus type I infection in patients with hematologic and nonhematologic diseases in an adult T-cell leukemia-endemic area of Japan. Cancer 1989 64: 1290 5.
13. Kawano R, Utsunomiya A, Matsuoka H, et al. [Registration of hematological disorders by the Kyushu Hematology Organization for Treatment (K-HOT) Study Group]. Rinsho Ketsueki 2004 45: 478 80.
14. Tajima K, Hinuma Y. Epidemiology of HTLV-I/II in Japan and the World. Tokyo: Japan Scientific Societies Press, 1992.
15. Hino S, Katamine S, Miyata H, Tsuji Y, Yamabe T, Miyamoto T. Primary prevention of HTLV-1 in Japan. Leukemia 1997 11 (Suppl. 3 57 9.
16. Cleghorn FR, Manns A, Falk R, et al. Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence. J Natl Cancer Inst 1995 87: 1009 14.
17. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991 79: 428 37.
18. Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, ed. Adult T-Cell Leukemia. Oxford: Oxford University Press, 1994: 221 37.
19. Eizuru Y, Tamura K, Minamishima Y, Ogata K, Tada S, Inoue S, Takeshita M, Kikuchi M. Cytomegalovirus infections in adult T-cell leukemia patients. J Med Virol 1987 23: 123 33.
20. Moriuchi Y, Yamada Y, Tomonaga M. [Infectious complications in patients with adult T-cell leukemia]. Kansenshogaku Zasshi 1992 66: 1444 8.
21. Tashiro T, Yamasaki T, Nagai H, Kikuchi H, Nasu M. Immunological studies on opportunistic infection and the development of adult T-cell leukemia. Intern Med 1992 31: 1132 6.
22. Kuwazuru Y, Hanada S, Furukawa T, et al. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 1990 76: 2065 71.
23. Ohno N, Tani A, Uozumi K, Hanada S, Furukawa T, Akiba S, Sumizawa T, Utsunomiya A, Arima T, Akiyama S. Expression of functional lung resistance - related protein predicts poor outcome in adult T-cell leukemia. Blood 2001 98: 1160 5.
24. Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000 96: 275 81.
25. Mori N, Fujii M, Cheng G, Ikeda S, Yamasaki Y, Yamada Y, Tomonaga M, Yamamoto N. Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways. Virus Genes 2001 22: 279 87.
26. Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA 1997 94: 13897 902.
27. Tomita M, Kikuchi A, Akiyama T, Tanaka Y, Mori N. Human T-cell leukemia virus type 1 tax dysregulates beta-catenin signaling. J Virol 2006 80: 10497 505.
28. Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988 6: 128 41.
29. Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol 1988 6: 1088 97.
30. Tobinai K, Shimoyama M, Minato K, et al. Japan Clinical Oncology Group trial of second-generation "LSG4 protocol" in aggressive lymphoma including ATL: prognostic factors and a predictive model. Proc Am Soc Clin Oncol 1994 13: 378a.
31. Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 2003 77: 164 70.
32. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001 113: 375 82.
33. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007 25: 5458 64. (Prepublished on October 29, 2007, as DOI:).
34. Taguchi H, Kinoshita KI, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 1996 12: 182 6.
35. Uozumi K, Nakahara K, Takatsuka Y, Ohno N, Makino T, Utsunomiya A, Hanada S, Arima T. Granulocyte colony-stimulating factor in the combination chemotherapy for adult T-cell leukemia (ATL). Leuk Lymphoma 1998 29: 407 14.
36. Matsushita K, Matsumoto T, Ohtsubo H, Fujiwara H, Imamura N, Hidaka S, Kukita T, Tei C, Matsumoto M, Arima N. Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. Leuk Lymphoma 1999 36: 67 75.
37. Kojima H, Hori M, Shibuya A, Nagasawa T, Miwa M, Abe T. Successful treatment of a patient with adult T-cell leukemia by daily oral administration of low-dose etoposide. Decrease in the amount of HTLV-I proviral DNA revealed by the polymerase chain reaction method. Cancer 1993 72: 3614 7.
38. Matsuoka H, Toyama T, Horinouchi M, Maeda K, Suzuki M, Kubuki Y, Komura K, Ishikawa T, Uno H, Tsubouchi H. [Successful chronic daily administration of oral etoposide for a case of adult T cell leukemia]. Gan To Kagaku Ryoho 1993 20: 1387 90.
39. Utsunomiya A, Takatsuka Y, Takeshita T, et al. [Oral administration of low-dose etoposide for maintenance chemotherapy in adult T cell leukemia patients]. Gan To Kagaku Ryoho 1994 21: 839 44.
40. Ezoe A, Kohda K, Hirayama Y, et al. [Two cases of adult T-cell leukemia. lymphoma (ATL) with long-term remission by chronic daily administration of low-dose etoposide]. Gan To Kagaku Ryoho 1995 22: 547 52.
41. Xinjia F, Matano S, Amitani S, Terahata S, Furusyo H, Yamamoto M, Sugimoto T. [Low-dose etoposide in a patient with adult T-cell leukemia/lymphoma who had severe complications]. Gan To Kagaku Ryoho 2001 28: 1269 72.
42. Ohno R, Masaoka T, Shirakawa S, et al. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group. Cancer 1993 71: 2217 21.
43. Tobinai K, Shimoyama M, Inoue S, Takayasu S, Mikuni C, Kozuru M, Oda S, Nakajima H. Phase I study of YK-176 (2′-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group. Jpn J Clin Oncol 1992 22: 164 71.
44. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994 12: 2588 93.
45. Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol 2003 77: 512 7.
46. Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, Ohashi Y, Ota K. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. Br J Cancer 1994 70: 771 4.
47. Teshima T, Akashi K, Shibuya T, Taniguchi S, Okamura T, Harada M, Sumida I, Hanada M, Niho Y. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer 1990 65: 327 32.
48. Dungerwalla M, Osuji N, Waldman AD, Al Jehani F, Mehta A, Tailor R, Wotherspoon A, Cogill G, Matutes E. Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia. Br J Haematol 2005 130: 511 5.
49. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999 93: 278 83.
50. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001 98: 3762 9.
51. Tanabe Y, An E, Futaki M, et al. [Successful treatment of adult T-cell leukemia with interferon-alpha-2b by systemic and local administration]. Rinsho Ketsueki 1990 31: 1572 5.
52. Sugie Y, Hayashi S, Shibuya T, Otsuka T, Okamura T, Harada M, Niho Y [Effect of topical injections of native alpha-interferon (HLBI) in the treatment of skin lesions of adult T cell leukemia: report of a case]. Rinsho Ketsueki 1990 31: 497 501.
53. Ohbayashi Y, Urabe A, Niitani K. Adult T-cell leukemia and interferon-alpha. Ann Intern Med 1988 109: 992.
54. Fujimoto T, Imamura N, Saito O, Fujimura K, Okada K, Kuramoto A. [Successful treatment of an adult T-cell leukemia with alpha-interferon]. Rinsho Ketsueki 1988 29: 1476 81.
55. Matsushima M, Yoneyama A, Nakamura T, Higashihara M, Yatomi Y, Tanabe A, Ohashi T, Oka H, Nakahara K. A first case of complete remission of beta-interferon sensitive adult T-cell leukemia. Eur J Haematol 1987 39: 282 7.
56. Tamura K, Makino S, Araki Y, Imamura T, Seita M. Recombinant interferon beta and gamma in the treatment of adult T-cell leukemia. Cancer 1987 59: 1059 62.
57. Takemori N, Hirai K, Onodera R, Saito N, Watanabe S, Namiki M. Splenectomy followed by local injections of interferon-alpha is effective for treating cutaneous-type adult T-cell leukaemia/lymphoma. Br J Dermatol 1993 129: 746 7.
58. Fujiwara H, Arima N, Akasaki Y, et al. Interferon-alpha therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma. Acta Haematol 2002 107: 213 9.
59. Ichimaru M, Kamihira S, Moriuchi Y, et al. [Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia]. Gan To Kagaku Ryoho 1988 15: 2975 81.
60. Oba T, Suzuki R, Miyamura K, Kodera Y. Huge mass of cutaneous-type adult T-cell leukemia which responded to interferon gamma. Intern Med 2007 46: 147.
61. Ijichi S, Izumo S, Nagai M, Shinmyozu K, Hall WW, Osame M. Anti-viral and immunomodulatory effects of interferon-alpha on cultured lymphocytes from patients with human T lymphotropic virus type I-associated myelopathy (HAM/TSP). J Neuroimmunol 1995 61: 213 21.
62. Saito M, Nakagawa M, Kaseda S, et al. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2004 189: 29 40.
63. Feng J, Misu T, Fujihara K, et al. Th1/Th2 balance and HTLV-I proviral load in HAM/TSP patients treated with interferon-alpha. J Neuroimmunol 2004 151: 189 94.
64. Tsukasaki K, Maeda T, Arimura K, Taguchi J, Fukushima T, Miyazaki Y, Moriuchi Y, Kuriyama K, Yamada Y, Tomonaga M. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant 1999 23: 87 9.
65. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001 27: 15 20.
66. Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 2005 19: 829 34.
67. Momita S, Ikeda S, Amagasaki T, Soda H, Yamada Y, Kamihira S, Tomonaga M, Kinoshita K, Ichimaru M. Survey of anti-human T-cell leukemia virus type I antibody in family members of patients with adult T-cell leukemia. Jpn J Cancer Res 1990 81: 884 9.
68. Tamaki H, Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation. N Engl J Med 2006 354: 1758 9.
69. Kato K, Kanda Y, Eto T, et al. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan marrow donor program. Biol Blood Marrow Transplant 2007 13: 90 9.
70. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005 105: 4143 5.
71. Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de The H, El-Sabban ME, Hermine O. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 2004 5: 664 72.
72. Gill PS, Harrington W Jr., Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995 332: 1744 8.
73. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995 332: 1749 51.
74. Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, Hamblin M, Kelsey S, Mir N, Reilly JT. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001 113: 779 84.
75. Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002 3: 276 82.
76. White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001 40: 287 94.
77. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986 83: 8333 7.
78. Copeland WC, Chen MS, Wang TS. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem 1992 267: 21459 64.
79. Bazarbachi A, Nasr R, El-Sabban ME, et al. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 2000 14: 716 21.
80. Uchida N, Otsuka T, Arima F, Shigematsu H, Fukuyama T, Maeda M, Sugio Y, Itoh Y, Niho Y. Correlation of telomerase activity with development and progression of adult T-cell leukemia. Leuk Res 1999 23: 311 6.
81. Sinha-Datta U, Horikawa I, Michishita E, Datta A, Sigler-Nicot JC, Brown M, Kazanji M, Barrett JC, Nicot C. Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. Blood 2004 104: 2523 31.
82. Kubuki Y, Suzuki M, Sasaki H, et al. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma 2005 46: 393 9.
83. Ji HJ, Rha SY, Jeung HC, Yang SH, An SW, Chung HC. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res Treat 2005 93: 227 36.
84. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996 16: 53 65.
85. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003 63: 579 85.
86. Falchetti A, Franchi A, Bordi C, et al. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res 2005 20: 410 8.
87. Brown T, Sigurdson E, Rogatko A, Broccoli D. Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann Surg Oncol 2003 10: 910 5.
88. Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, Furst AJ, Feun L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol 2003 23: 173 9.
89. Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006 108: 1021 9.
90. Datta A, Nicot C. Telomere attrition induces a DNA double-strand break damage signal that reactivates p53 transcription in HTLV-I leukemic cells. Oncogene (Prepublished on August 20, 2007, as DOI:).
91. Tawara M, Hogerzeil SJ, Yamada Y, et al. Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. Cancer Lett 2006 234: 249 55.
92. Harrington WJ Jr., Cabral L, Cai JP, Chan ASS, Wood C. Azothymidine and interferon-alpha are active in AIDS-associated small non-cleaved cell lymphoma but not large-cell lymphoma. Lancet 1996 348: 833.
93. Tosi P, Gherlinzoni F, Mazza P, et al. 3′-Azido 3′-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas. Blood 1997 89: 419 25.
94. Langford A, Ruf B, Kunze R, Pohle HD, Reichart P. Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). Br J Dermatol 1989 120: 709 13.
95. Oksenhendler E, Clauvel JP, Jouveshomme S, Davi F, Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol 1998 57: 266.
96. Roychowdhury S, Peng R, Baiocchi RA, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 2003 63: 965 71.
97. Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Toomey NL, Cabral L, Whitby D, Barber GN, Dittmer DP, Harrington WJ Jr. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood 2005 106: 235 40.
98. Matsushita S, Mitsuya H, Reitz MS, Broder S. Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. J Clin Invest 1987 80: 394 400.
99. Macchi B, Faraoni I, Zhang J, Grelli S, Favalli C, Mastino A, Bonmassar E. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J Gen Virol 1997 78 (Pt 5 1007 16.
100. Balestrieri E, Forte G, Matteucci C, Mastino A, Macchi B. Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrob Agents Chemother 2002 46: 3080 3.
101. Garcia-Lerma JG, Nidtha S, Heneine W. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. J Infect Dis 2001 184: 507 10.
102. Machuca A, Rodes B, Soriano V. The effect of antiretroviral therapy on HTLV infection. Virus Res 2001 78: 93 100.
103. Taylor GP, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology 2006 3: 63.
104. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 2003 17: 71 97.
105. Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998 103: 721 8.
106. Ishitsuka K, Ikeda R, Utsunomiya A, et al. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation. Leuk Lymphoma 2002 43: 1107 14.
107. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H, Bazarbachi A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000 96: 2849 55.
108. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003 101: 4576 82.
109. Brown M, Bellon M, Nicot C. Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood 2007 109: 1653 9.
110. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004 5: 130 4.
111. Ishitsuka K, Suzumiya J, Aoki M, Ogata K, Hara S, Tamura K. Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica 2007 92: 719 20.
112. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993 82: 1701 12.
113. Tendler CL, Greenberg SJ, Burton JD, Danielpour D, Kim SJ, Blattner WA, Manns A, Waldmann TA. Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis. J Cell Biochem 1991 46: 302 11.
114. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995 86: 4063 75.
115. Osborne GE, Pagliuca A, Ho A, du Vivier AW. Novel treatment of Sezary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody). Br J Dermatol 2006 155: 617 20.
116. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000 18: 1622 36.
117. Di Venuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin Lymphoma 2003 4: 176 8.
118. Janik JE, Morris JC, Stetler-Stevenson M, Gao WW, O'Hagan D, Moses LS, Taylor M, McEwen C, Hammershaimb LD, Waldmann TA. Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. J Clin Oncol 2005 23: 174s 174s.
119. Mone A, Puhalla S, Whitman S, et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia. Blood 2005 106: 3380 2.
120. Ravandi F, Faderl S. Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res 2006 30: 103 5.
121. d'Amore F, Relander T, Hagberg H, et al. HuMax-CD4 (Zanolimumab), a fully human monoclonal antibody: early results of an ongoing clinical trial in CD4(+) peripheral T-cell lymphoma of non-cutaneous type. Blood 2005 106: 937a 937a.
122. Callens C, Moura IC, Lepelletier Y, et al. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia (Prepublished on September 27, 2007; as DOI:).
123. Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002 99: 1505 11.
124. Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 2004 10: 7529 39.
125. Maeda Y, Miyatake J, Sono H, Matsuda M, Tatsumi Y, Horiuchi F, Irimajiri K, Horiuchi A. 13-cis retinoic acid inhibits growth of adult T cell leukemia cells and causes apoptosis; possible new indication for retinoid therapy. Intern Med 1996 35: 180 4.
126. Furuke K, Sasada T, Ueda-Taniguchi Y, Yamauchi A, Inamoto T, Yamaoka Y, Masutani H, Yodoi J. Role of intracellular redox status in apoptosis induction of human T-cell leukemia virus type I-infected lymphocytes by 13-cis-retinoic acid. Cancer Res 1997 57: 4916 23.
127. Fujimura S, Suzumiya J, Anzai K, Ohkubo K, Hata T, Yamada Y, Kamihira S, Kikuchi M, Ono J. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res 1998 22: 611 8.
128. Okudaira T, Tomita M, Uchihara JN, et al. NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-kappaB signal pathway. Mol Cancer Ther 2006 5: 704 12.
129. Darwiche N, Abou-Lteif G, Bazarbachi A. Reactive oxygen species mediate N-(4-hydroxyphenyl)retinamide-induced cell death in malignant T cells and are inhibited by the HTLV-I oncoprotein Tax. Leukemia 2007 21: 261 9.
130. Tsukasaki K, Fujimoto T, Hata T, Yamada Y, Kamihira S, Tomonaga M. Concomitant complete remission of APL and smoldering ATL following ATRA therapy in a patient with the two diseases simultaneously. Leukemia 1995 9: 1797 8.
131. Maeda Y, Yamaguchi T, Ueda S, Miyazato H, Matsuda M, Kanamaru A. All-trans retinoic acid reduced skin involvement of adult T-cell leukemia. Leukemia 2004 18: 1159 60.
132. Inozume T, Matsue H, Furuhashi M, et al. Successful use of etretinate for long-term management of a patient with cutaneous-type adult T-cell leukaemia/lymphoma. Br J Dermatol 2005 153: 1239 41.
133. Nawata H, Maeda Y, Sumimoto Y, Miyatake J, Kanamaru A. A mechanism of apoptosis induced by all-trans retinoic acid on adult T-cell leukemia cells: a possible involvement of the Tax/NF-kappaB signaling pathway. Leuk Res 2001 25: 323 31.
134. Darwiche N, El-Sabban M, Bazzi R, Nasr R, Al-Hashimi S, Hermine O, de The H, Bazarbachi A. Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells. Hematol J 2001 2: 127 35.
135. Richardson S, Budgin JB, Junkins-Hopkins JM, Vittorio CC, Lee J, Miller WT Jr., Rook AH, Kim EJ. Low-dose bexarotene and low-dose interferon alfa-2b for adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus 1. Arch Dermatol 2005 141: 301 4.
136. Ballard DW, Bohnlein E, Lowenthal JW, Wano Y, Franza BR, Greene WC. HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science 1988 241: 1652 5.
137. Lacoste J, Petropoulos L, Pepin N, Hiscott J. Constitutive phosphorylation and turnover of I kappa B alpha in human T-cell leukemia virus type I-infected and Tax-expressing T cells. J Virol 1995 69: 564 9.
138. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, Yamamoto N. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 1999 93: 2360 8.
139. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002 62: 1083 6.
140. Nasr R, El-Sabban ME, Karam JA, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 2005 24: 419 30.
141. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004 18: 1357 63.
142. Hamamura RS, Ohyashiki JH, Kurashina R, Kobayashi C, Zhang Y, Takaku T, Ohyashiki K. Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer 2007 97: 1099 105.
143. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006 24: 2105 12.
144. Yoshioka R, Yamaguchi K, Yoshinaga T, Takatsuki K. Pulmonary complications in patients with adult T-cell leukemia. Cancer 1985 55: 2491 4.
145. Iroi A, Miyashita N, Nakamura S, Ohizumi H, Mizuno Y. [A patient with marked immunodeficiency in an HTLV-I carrier: a case report]. Rinsho Shinkeigaku 2000 40: 135 9.
146. Itoh T, Ban H, Takamura R, Yoshikawa T, Kodama T, Tamagaki Y. [A HTLV-I carrier initially treated for Pneumocystis carinii pneumonia]. Nihon Kokyuki Gakkai Zasshi 2002 40: 822 6.
147. Kawahigashi N, Furukawa Y, Tara M, Niina K. [Pneumocystis carinii pneumonia in a HTLV-I carrier with monoclonal proliferation of HTLV-I infected lymphocyte]. Rinsho Ketsueki 1996 37: 317 22.
148. Kuwazuru Y, Hanada S, Uematsu T, Saitou T, Makino T, Uozumi K, Hashimoto S. [Pneumocystis carinii pneumonia in a HTLV-I carrier terminating with acute type of adult T-cell leukemia]. Rinsho Ketsueki 1988 29: 2132 5.
149. Moriyama K, Muranishi H, Nishimura J, Tanaka K, Asayama R, Takita A. Immunodeficiency in preclinical smoldering adult T-cell leukemia. Jpn J Clin Oncol 1988 18: 363 9.
150. Tashiro T. [Pulmonary complications in patients with adult T-cell leukemia]. Nihon Kyobu Shikkan Gakkai Zasshi 1992 30: 756 62.
151. Ishitsuka K, Ikeda S, Izumi Y, et al. [Infection control for the treatment of hematological malignancies: a survey of the Kyushu Hematology Organization for Treatment Study Group (K-HOT)]. Rinsho Ketsueki 2003 44: 483 90.
152. Ikeda K, Ohno H, Hane M, et al. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994 79: 1322 7.
153. Motokura T, Fukumoto S, Takahashi S, Watanabe T, Matsumoto T, Igarashi T, Ogata E. Expression of parathyroid hormone-related protein in a human T cell lymphotrophic virus type I-infected T cell line. Biochem Biophys Res Commun 1988 154: 1182 8.
154. Watanabe T, Yamaguchi K, Takatsuki K, Osame M, Yoshida M. Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be
155. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 2002 99: 634 40.
156. Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y. Macrophage inflammatory protein-1alpha induces hypercalcemia in adult T-cell leukemia. J Bone Miner Res 2004 19: 1105 11.
157. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005 352: 373 9.